JPRN-jRCT1080222951未知Unknown
Drug use surveillance of Takecab tablets Supplement to Helicobacter pylori eradication
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点目标入组 500 人开始时间: 2015年8月31日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Participants who meet the following criteria will be included.
- •1.Participants receiving H. pylori eradication treatment for the first time
- •2.Participants for whom H. pylori eradication with Takecab tablets or proton pump inhibitor + amoxicillin + clarithromycin was found unsuccessful and who will receive eradication treatment with amoxicillin and metronidazole
排除标准
- •Participants who meet any of the following criteria will not be included. Refer to the Contraindications and Precautions section of the package insert of antimicrobials used in triple therapy.
- •1.Participants with previous history of hypersensitivity to ingredients in Takecab tablets
- •2.Participants taking atazanavir sulfate or rilpivirine hydrochloride
研究者
相似试验
招募中
不适用
Protocol Number; CINC280AJP01MET exon 14 skipping mutation-positive unresectable advanced/recurrent non-small cell lung cancerJPRN-jRCT2031200409Sugimoto Toshiya100
未知
Unknown
EGEND study (Lansoprazole effectiveness on GERD patients with dyspepsia symptoms)Gastroesophageal reflux disease with dyspepsia symptomsJPRN-jRCT1080222261TAKEDA PHARMACEUTICAL COMPANY LTD.15,000
已完成
Unknown
Drug Use Surveillance of Vonoprazan for Gastric Ulcer, Duodenal Ulcer, and Reflux EsophagitisGastric ulcer, duodenal ulcer, and reflux esophagitisJPRN-jRCT1080223122Takeda Pharmaceutical Company Limited3,183
招募中
Unknown
Post-marketing Surveillance Protocol Number; CDRB436I1401BRAF V600E mutation-positive unresectable advanced or recurrent solid tumorJPRN-jRCT2031230623sato masayuki90
进行中（未招募）
不适用
Survey of Cabozantinib Used To Treat People With Renal Cell CarcinomaRenal cell carcinomaJPRN-jRCT2031210003Contact for Clinical Trial Information388